

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




22

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07K 3/02, 3/22, 15/06 C12N 5/06, A23C 21/00		A1	(11) International Publication Number: WO 92/00994
			(43) International Publication Date: 23 January 1992 (23.01.92)
(21) International Application Number: PCT/AU91/00303		(74) Agent: PHILLIPS, ORMONDE & FITZPATRICK; 367 Collins Street, Melbourne VIC 3000 (AU).	
(22) International Filing Date: 9 July 1991 (09.07.91)			
(30) Priority data: PK 1170 13 July 1990 (13.07.90) AU		(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.	
(71) Applicant (for all designated States except US): GROPEP PTY. LTD. [AU/AU]; 39 Winwood Street, Thebarton, S.A. 5031 (AU).		Published With international search report.	
(72) Inventors; and (75) Inventors/Applicants (for US only) : BALLARD, Francis, John [AU/AU]; 23 Lowan Avenue, Glenalta, S.A. 5031 (AU). FRANCIS, Geoffrey, Leonard [AU/AU]; 9 Joyleen Court, Athelstone, S.A. 5076 (AU). REGESTER, Geoffrey, Owen [AU/AU]; Unit 5, 2 Cassie Street, Collinswood, S.A. 5081 (AU).			

(54) Title: GROWTH-PROMOTING AGENT



(57) Abstract

A milk product extract composition including a plurality of cell growth stimulating factors, extracted from milk product, in concentrated form; said factors having basic to approximately neutral isoelectric points. Cell culture compositions and pharmaceutical or veterinary compositions including the above milk product extract. Methods for preparing and using the same.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

-1-

GROWTH-PROMOTING AGENT

This invention relates to the growth of animal cells in a cell culture composition. More specifically it relates to the provision of a cell culture composition including a cheese whey extract composition.

Animal cells are grown in culture to provide a number of Pharmaceutical, Diagnostic and Veterinary products including Human vaccines, Lymphokines, Hormones, Monoclonal antibodies, Other Pharmaceutically active protein products, Veterinary hormones and for Research and Development and Diagnostic purposes.

The growth of animal cells requires a defined isotonic medium that contains salts, nutrients, lipid precursors, nucleic acid precursors, vitamins and amino acids that are formulated to mimic the medium that would normally bathe those cells in vivo. Examples in common use include Eagle's Minimal Essential Medium, Dulbecco's-modified Eagle's Minimal Essential Medium (DMEM), Medium 199, RPMI 1640 medium and Ham's F12 Medium. However, virtually no animal cells will grow in such a medium, but require the co-addition of serum. Fetal bovine serum is frequently used as it is more effective than serum obtained from post-natal animals and it contains only minimal concentrations of immunoglobulins which otherwise could have undesirable effects.

The supply of fetal bovine serum is limited by the number of pregnant cows slaughtered. It also has undesirable lot-to-lot variations and may include toxins. Particular concern surrounds its use for the eventual production of recombinant proteins and other pharmaceuticals for human use because the serum may also contain viruses that are harmful to humans and may be carried through a purification protocol that yields the desirable product. Principally for these reasons, extensive efforts have been directed towards the replacement of serum by pure ingredients. Examples of such ingredients are growth factors, hormones and cell attachment factors. Unfortunately, the requirements of each cell type being grown are different and are difficult

-2-

to establish. Frequently it has not proved possible to achieve equivalent growth properties or equivalent yields of cell products with "serum-free" media as can be obtained with medium containing fetal bovine serum.

5 The limited availability of fetal bovine serum, its lot-to-lot variability, its resultant considerable cost as well as the deficiencies of "serum-free" media described above have prompted the investigation of other biological fluids as potential replacements in cell culture media.
10 Some progress has been reported in the prior art with bovine milk and bovine colostrum as evidenced by the following selected reports: M. Klagsbrun: "Human milk stimulates DNA synthesis and cell proliferation in cultured fibroblasts" (Proc. Natl. Acad. Sci. USA 75, 5057, 1978);
15 M. Klagsbrun & J. Neumann: "The serum-free growth of Balb/c 3T3 cells in medium supplemented with bovine colostrum" (J. Supramol. Struct. 11, 349, 1979).

 The prior art also includes U.S. Patent 4,440,860 to M. Klagsbrun which describes "compositions and methods
20 for promoting cell growth featuring, in one aspect, cell culture media containing milk or colostrum and fibronectin; fibronectin is preferably pre-coated onto the culture substrate" and Japan Patent JP 59166879 to Morinaga "A culture medium for cell incubation -
25 containing milk or milk components". Ultrafiltrates of milk whey have also been used to support the growth of cultured cells, as in European Patent 86401911.2 to G. Linden et al. "Fractions de lait, Procédée d'obtention de ces fractions et milieux de culture cellulaires renfermant
30 ces fractions" and O. Damerdjji et al. "Utilization of whey fractions as a substitute for fetal calf serum in culture media" (Biotech. Tech. 2, 235, 1988).

 Despite this progress a successful alternative to fetal bovine serum is yet to be located.

35 It is accordingly an object of the present invention to overcome, or at least alleviate one or more of the difficulties or deficiencies related to the prior art.

 Accordingly in a first aspect of the present invention there is provided a milk product extract

composition including a plurality of cell growth stimulating factors, extracted from milk product, in concentrated form; said factors having basic to approximately neutral isoelectric points.

5 By the term "milk product" we mean an extract from human or animal milk product in which the salt and/or main protein constituents thereof are reduced or eliminated. Examples of milk extract include cheese whey extracts, skim milk extract and acid (casein) whey.

10 The present invention will be more fully described with reference to the preferred cheese whey extracts. However, this is illustrative only and should not be taken as a restriction on the generality of the invention.

15 Preferably the milk product extract composition is a cheese whey extract composition.

The cheese whey extract composition may be formed from cheese whey wherein the salt and/or main protein constituents thereof are reduced or eliminated.

20 The milk product extract composition may include less than approximately 1% w/w salt, based on the total weight of the composition. The milk product extract may include less than approximately 0.5% w/w casein, alpha lactalbumin, beta lactoglobulin, immunoglobulin or
25 albumin, based on the total weight of the composition.

The milk product extract composition according to this aspect of the present invention may be utilised in the promotion of cell growth and proliferation in vitro as discussed below. The milk product extract composition may
30 be utilised in stimulation of surface wound repair in vivo, in mammals as discussed below.

Surprisingly, the milk product extract composition may support the growth of animal cells at lower protein concentrations than achieved with fetal
35 bovine serum, yet with an efficacy comparable to fetal bovine serum for several cell types.

Alternatively, the cheese whey extract may be used as a supplement to media containing low concentrations of fetal bovine serum in order to achieve

better growth rates of cultured cells and to conserve the use of fetal bovine serum.

Cheese whey is a by-product of the cheese industry that has had essentially all the fat and casein removed during cheese manufacture. At the present state of the art cheese whey is essentially valueless, and indeed it may represent a net cost to the industry since it is a potential pollutant.

Cheese whey for example is a low protein, high salt product available in tonne amounts from cheese manufacture. The main protein constituents present in cheese whey are alpha lactalbumin (α LA) and beta lactoglobulin (BLG), which usually account for more than 90% of the proteins present. Significant amounts of serum albumin, immunoglobulins and residual casein may be present. All of these proteins have acidic isoelectric points. In contrast, the main protein factors that stimulate the growth of animal cells have basic isoelectric points. Examples include the growth factors basic FGF, IGF-I, des(1-3)IGF-I and PDGF. It is postulated that the extraction of the basic factors present in milk products such as cheese whey in the virtual absence of the otherwise abundant acidic proteins may account for the surprising efficacy of the milk product extract composition.

Accordingly in a further aspect of the present invention, there is provided a method for preparing a milk product extract composition including a plurality of cell growth stimulating factors, extracted from milk product in concentrated form; said factors having basic to approximately neutral isoelectric points, which method includes

providing

- a source of milk product;
- a cationic exchange resin; and
- a buffer solution;

contacting the milk product with the cation exchange resin such that the more basic components of the milk product are absorbed thereon;

eluting the cationic exchange resin with the buffer solution; and

filtering the eluate to remove salt therefrom.

5 The desorption of the basic proteins from the ion exchange resin leads to a preparation enriched in cell growth stimulating factors. The eluate may be concentrated and filtered utilising any suitable technique. The eluate may be concentrated for example by conventional ultrafiltration methods or other procedures
10 to yield a mixture of proteins which supports the growth of animal cells when added to protein-free media such as DMEM.

The source of milk product may be a milk product filtrate substantially free of insoluble material.
15 Accordingly the preparation method may include the preliminary step of

filtering the milk product to remove insoluble materials therefrom.

The milk product may be filtered through a suitable sieve. The milk product may be filtered through
20 a hollow fiber cartridge of defined porosity.

The cationic exchange resin may be of any suitable type. A Sepharose - based cation exchange gel may be used. The contacting step may be conducted at
25 neutral to basic pH. The contacting step may be conducted at a pH of approximately 6.5 to 8.0.

The cationic exchange resin may be equilibrated with a suitable buffer at a pH of approximately 6.5 to 8.0. An aqueous sodium citrate buffer may be used. The
30 elution steps may be conducted utilising a suitable eluate. A salt solution may be used. A buffered saline solution may be used.

Thus in a preferred form of this aspect of the present invention the method of preparing a milk product
35 extract composition may include treating milk product sequentially by:

subjecting the milk product to a filtration step, to remove insoluble materials therefrom;

adjusting the pH of the filtrate to between

approximately 6.5 and 8.0;

contacting the filtrate with a cationic exchange resin;

5 eluting from the cation exchange resin at high ionic strength and high pH with a suitable buffer solution; and

subjecting the eluate to a concentration step and diafiltration step to remove salt therefrom.

10 Alternatively, the elution from the cation exchange resin is achieved at high ionic strength but without adjusting pH, such that the cell growth stimulating factors are recovered.

In this embodiment the cell growth stimulating factors are eluted with less extraneous protein.

15 In a further aspect of the isolation of a suitable extract from cheese whey, the eluant may be treated at high temperature and centrifuged. This modification removes additional protein. Accordingly, the method may further include subjecting the eluant to a heat
20 treatment to reduce the content of extraneous protein.

The milk product extract composition may be sterilized and optionally freeze-dried for storage. The freeze-dried material may be dissolved in sterile saline for addition to cells in culture.

25 In a further aspect of the present invention there is provided a cell culture composition including an effective amount of a milk product extract composition including

30 a plurality of cell growth stimulating factors, extracted from milk product, in concentrated form; said factors having basic to approximately neutral isoelectric points; and

a culture medium.

35 The culture medium may be a substantially protein-free isotonic culture medium. The substantially protein-free isotonic culture medium may be Dulbecco's-modified Eagle's minimal Essential Medium (DMEM).

It has been found that an approximately

equivalent growth rate of human skin fibroblasts to that achieved with 5% Fetal Bovine Serum may be achieved with approximately 20 μ g of cell growth stimulating factors extracted from cheese whey according to the preferred aspect of the present invention per 100 μ l of medium.

Alternatively a small but effective amount of fetal bovine serum may be utilised as the culture medium. It has been found that the addition of approximately 25 μ g of cell growth stimulating factors per 100 μ l of medium containing approximately 2% fetal bovine serum will increase the growth rate of Balb C/3T3 cells to that rate otherwise achieved with 10% fetal bovine serum.

Other additions may be made to the medium, depending on the cell type, including growth factors, attachment factors or low amounts of serum.

In a preferred form, the present invention provides a cell culture composition, as described above, wherein the milk product extract is present in media at a protein concentration of approximately 10 to 20,000 micrograms per ml, preferably 100 to 2,000 micrograms per ml.

Accordingly in a still further aspect of the present invention there is provided a method for culturing cells which method includes

providing
a source of animal cells; and
a cell culture composition including an effective amount of a milk product extract composition including

a plurality of cell growth stimulating factors, extracted from milk product, in concentrated form; said factors having basic to approximately neutral isoelectric points; and

a substantially protein-free isotonic culture medium; and

culturing the cells in the cell culture composition for a time sufficient, and at a temperature sufficient to achieve a predetermined cell concentration.

The cell culture method may be conducted at ambient temperature or above. A temperature in the range of approximately 35 to 40°C may be used. The cell culture process may be conducted in an incubator, for example a humidified incubator.

The cell culture method may be conducted on any suitable surface or in suspension. Tissue culture plates may be used.

The cell culture method may continue for a period of approximately 1 to 5 days depending on the cell concentration desired.

Although the method in particular applies to the growth of animal cells in vitro, it can also be applied to animals, including humans, that have surface wounds.

Accordingly, in a further aspect, the present invention provides a pharmaceutical or veterinary composition for the treatment of surface wounds, which composition includes:

an effective amount of a milk product extract composition including a plurality of cell growth promoting factors, extracted from milk product in concentrated form; said factors having basic to approximately neutral isoelectric points; and

a pharmaceutically or veterinarily-acceptable diluent, carrier or excipient therefor.

The pharmaceutical or veterinary composition may further include an effective amount of at least one active ingredient.

The at least one active ingredient may be selected from antibiotics, antiseptics, other growth promotants, anaesthetics, and the like, and mixtures thereof.

The pharmaceutical or veterinary composition may be adapted for administration in any suitable manner. The composition may be adapted for internal or topical administration. The composition may be in an oral, injectable or topical form. Topical administration is preferred. The composition may take the form of a wash, lotion, cream, ointment or gel.

There are no limitations to the type of surface wound that may be treated, and these include, but are not limited to burns, ulcers, lacerations and penetrations.

Accordingly, in a further aspect of the present invention there is provided a method of treating surface wounds in animals, including humans, which method includes administering to the patient to be treated an effective amount of a pharmaceutical or veterinary composition, which composition includes

an effective amount of a milk product extract composition including a plurality of cell growth promoting factors, extracted from milk product in concentrated form; said factors having basic to approximately neutral isoelectric points; and

a pharmaceutically or veterinarily-acceptable diluent, carrier or excipient therefor.

The method can also be applied to animals, including humans, that have gastrointestinal injuries, diseases or ulcers.

Accordingly, in a further aspect, the present invention provides a pharmaceutical or veterinary composition for the treatment of gastrointestinal injuries, diseases or ulcers, which composition includes:

an effective amount of a milk product extract composition including a plurality of cell growth promoting factors, extracted from milk product in concentrated form; said factors having basic to approximately neutral isoelectric points; and

a pharmaceutically or veterinarily-acceptable diluent, carrier or excipient therefor.

There are no limitations to the type of gastrointestinal injury, disease or ulcer that may be treated.

Accordingly, in a still further aspect of the present invention, there is provided a method for the treatment of gastrointestinal injuries, diseases or ulcers, which method includes administering to the patient to be treated an effective amount of a pharmaceutical or veterinary composition, which composition includes

-10-

an effective amount of a milk product extract composition including cell growth promoting factors, extracted from milk product in concentrated form and having a basic to approximately neutral isoelectric point;
5 and

a pharmaceutically or veterinarily acceptable diluent, carrier or excipient therefor.

The present invention will now be more fully described with respect to the following examples. It
10 should be understood, however, that the description following is illustrative only, and should not be taken in any way as a restriction on the generality of the invention described above.

EXAMPLE 1

15 Preparation of a fraction from cheese whey (GFE) that is enriched in growth-promoting activity

Pasteurized whey obtained as an end product of cheese manufacture was filtered through a 10 micron screen and a 0.2 micron Sartorius Microsart Sartocon II module to
20 remove solids. The ultrafiltrate was adjusted to pH 6.5 and applied to a column of S-Sepharose Fast Flow S cation exchange resin (Pharmacia) that had been equilibrated with 50 mM sodium citrate buffer at pH 6.5. After washing the column with the same buffer the absorbed material was
25 eluted by a solution of 1M NaCl containing 0.25 M NH_4OH . This eluate was diafiltered against water until the conductivity reached 0 μS and then concentrated by ultrafiltration; both processes using a 3KDa-excluding membrane. The resultant preparation was freeze-dried to
30 produce the "GFE" product.

A preparation from 30 litres of cheese whey containing 18g protein yielded a GFE extract containing 2.66 g protein.

EXAMPLE 2

35 Preparation of a fraction from cheese whey that is enriched in growth-promoting activity and depleted in extraneous protein including lactoferrin (GFE-2)

Pasteurized whey was filtered and applied to a column of S-Sepharose and the column washed as in Example

-11-

1. Elution was accomplished with a solution containing 0.4M NaCl added to 10mM sodium citrate pH6.5. This GFE-2 was diafiltered against water, concentrated and freeze-dried as described in Example 1.

5 A preparation from 30 litres of cheese whey which contained 18g protein yielded a GFE-2 extract containing 0.56g protein.

EXAMPLE 3

10 Preparation of a modified GFE-2 fraction that is also depleted in extraneous protein including lactoperoxidase (GFE-3)

The freeze-dried GFE-2 (Example 2) was dissolved at a concentration of 25 mg/ml and heated at 80°C for 2.5 min. The heated sample was cooled rapidly and
15 centrifuged. The clear supernatant was passed through a 0.22 µm filter before use. This solution contained 50% of the protein present in GFE-2 and approximately 10% lactoperoxidase.

EXAMPLE 4

20 Stimulation of the growth of cultured cells by cheese whey extracts (Examples 1, 2) compared with fetal bovine serum

Prior to addition to culture media, the freeze-dried powders (GFE, GFE-2) were first suspended in Dulbecco's Phosphate-buffered saline and sterilised by
25 passage through a 0.22 µm filter.

This example utilises the cell lines L6 (rat myoblast), Balb C/3T3 (mouse fibroblast) and SF1972 (human diploid skin fibroblast).

Each cell line was subcultured on to 96-place
30 tissue culture plates in Dulbecco-Modified Eagles's Minimal Essential Medium (DMEM) containing 5% fetal bovine serum and left in a 5% CO₂, 37°C, humidified incubator overnight to ensure attachment of the cells. Sterile techniques were used throughout. The plates were
35 thoroughly washed in DMEM to remove any residual serum and the whey extract (GFE or GFE-2) or fetal bovine serum (FBS) added at the indicated concentrations. The total volume in each well was 0.1 ml at 37°C, 5% CO₂ and 100% humidity.

-12-

After a further 2 days the plates were washed, fixed and the cell numbers quantified using an automated methylene blue method (M.H. Oliver et al., J. Cell Sci. 92, 513, 1989). Growth is expressed as the percentage increase in absorbance units relative to the increase in absorbance produced by growing the cells in DMEM containing 5% fetal bovine serum (Figure 1).

This example shows that in all three cell lines GFE and GFE-2 stimulate growth as well as fetal bovine serum. Moreover, in Balb C/3T3 and SF1972 cells GFE-2 is active at approximately one tenth the protein content as fetal bovine serum.

EXAMPLE 5

Stimulation of the growth of cultured cells by extracts of cheese whey depleted in extraneous protein including lactoperoxidase (GFE-3, Example 3) compared with GFE-2 (Example 2)

The experimental details were exactly as described in Example 4 except that the data are expressed as the protein content ($\mu\text{g}/100\mu\text{l}$ well) that achieved the same growth response as was achieved with 5% fetal bovine serum (see Table 1).

TABLE 1

Growth of Cells in the presence of GFE-2 or GFE-3

Cell Type	Extract	Concentration ($\mu\text{g}/100\mu\text{l}$) achieving growth equivalent to 5% fetal bovine serum
L6	GFE-2	100
	GFE-3	63
Balb C/3T3	GFE-2	15
	GFE-3	6
SF1972	GFE-2	8
	GFE-3	4

Clearly less GFE-3 is required to stimulate growth than GFE-2. Also since 5% fetal bovine serum has a

protein content of 250 $\mu\text{g}/100\mu\text{l}$, both GFE-2 and GFE-3 are very substantially more potent than 5% fetal bovine serum, especially for Balb C/3T3 cells and human skin fibroblasts (SF1972).

5

EXAMPLE 6

Growth effects of cultured cells produced by supplementing medium containing 2% fetal bovine serum with GFE-2 extracts (Example 2)

10 The experimental details were exactly as described in Example 4 except that the human lung fibroblast line (HEL) replaced the human skin fibroblast line (SF1972). Data are expressed as absorbances achieved after growth of the cells for 2 days (see Table 2).

TABLE 2

15 Growth of Cells with GFE-2 added in the presence of 2% fetal bovine serum

	Fetal Bovine Serum (%)	GFE-2 ($\mu\text{g}/100\mu\text{l}$)	Increases in absorbance		
			L6 cells	Balb C/3T3 cells	HEL cells
20	2	0	0.618	0.126	0.165
	5	0	0.998	0.270	0.210
25	10	0	1.309	0.502	0.345
	2	5	1.010	0.294	0.322
	2	25	1.108	0.585	0.388
	2	50	1.157	0.698	0.389
30	2	100	1.370	0.799	0.374

35 This experiment demonstrates that low amounts of GFE-2 added to medium containing only 2% fetal bovine serum can increase the growth rate to that achieved with 10% fetal bovine serum. The approximate amount of GFE-2 required to achieve this growth enhancement was 100 $\mu\text{g}/100\mu\text{l}$ in L6 cells, 25 $\mu\text{g}/100\mu\text{l}$ in Balb C/3T3 cells and only 5 $\mu\text{g}/100\mu\text{l}$ in HEL cells. Such an

-14-

enhancement represents a very substantial saving of fetal bovine serum.

Finally, it is to be understood that various other modifications and/or alterations may be made without departing from the spirit of the present invention as outlined herein.

10

15

20

25

30

35

Claims :

-15-

1. A milk product extract composition including a plurality of cell growth stimulating factors, extracted from milk product, in concentrated form; said factors having basic to approximately neutral isoelectric points.
- 5 2. A composition according to claim 1, wherein the milk product extract composition includes less than approximately 0.5% w/w casein, alpha lactalbumin, beta lactoglobulin, immunoglobulin or albumin, based on the total weight of the composition.
- 10 3. A composition according to claim 2, wherein the residual extraneous protein content of the milk product is further reduced.
4. A composition according to claim 3 wherein the milk product extract composition is a cheese whey extract
15 composition.
5. A method for preparing a milk product extract composition including a plurality of cell growth stimulating factors, extracted from milk product, in concentrated form; said factors having basic to
20 approximately neutral isoelectric points, which method includes
 providing
 a source of milk product;
 a cationic exchange resin; and
25 a buffer solution;
 contacting the milk product with the cation exchange resin such that the more basic components of the milk product are absorbed thereon;
 eluting the cationic exchange resin with the
30 buffer solution; and
 filtering the eluate to remove salt therefrom.
6. A method according to claim 5, further including treating milk product sequentially by
 subjecting the milk product to a filtration step,
35 to remove insoluble materials therefrom;
 adjusting the pH of the filtrate to between approximately 6.5 and 8.0;
 contacting the filtrate with a cationic exchange resin;

eluting from the cation exchange resin at high ionic strength and high pH with a suitable buffer solution; and

5 subjecting the eluate to a concentration step and diafiltration step to remove salt therefrom.

7. A method according to claim 6, the elution step is conducted without adjusting pH, such that cell growth stimulating factors are recovered.

8. A method according to claim 7, further including
10 subjecting the eluant to a heat treatment to reduce extraneous proteins.

9. A cell composition including an effective amount of a milk product extract composition including
15 a plurality of cell growth stimulating factors, extracted from milk product, in concentrated form; said factors having basic to approximately neutral isoelectric points; and

 a culture medium.

10. A cell composition according to claim 9 wherein
20 the culture medium is a substantially protein-free culture medium.

11. A cell composition according to claim 9 wherein the culture medium contains fetal bovine serum.

12. A cell culture composition according to claim 10,
25 wherein the extraneous protein content of the milk product is further reduced.

13. A cell culture composition according to claim 12, wherein the milk product extract composition is present at a protein concentration of approximately 10 to 20,000
30 micrograms per ml of culture medium.

14. A method for culturing cells which method includes providing

 a source of animal cells; and

35 a cell culture composition including an effective amount of a milk product extract composition including

 a plurality of cell growth stimulating factors, extracted from milk product, in concentrated form; said factors having basic

-17-

to approximately neutral isoelectric points;
and

a substantially protein-free isotonic
culture medium; and

5 culturing the cells in the cell culture
composition for a time sufficient, and at a temperature
sufficient to achieve a predetermined cell concentration.

15. A method according to claim 14, wherein the cells
are cultured at a temperature in the range of
10 approximately 35°C to 40°C for a period of approximately 1
to 5 days.

16. A pharmaceutical or veterinary composition for
the treatment of surface wounds, which composition
includes:

15 an effective amount of a milk product extract
composition including a plurality of cell growth promoting
factors, extracted from milk product in concentrated form;
said factors having basic to approximately neutral
isoelectric points; and

20 a pharmaceutically or veterinarily-acceptable
diluent, carrier or excipient therefor.

17. A composition according to claim 16, further
including an effective amount of at least one active
ingredient selected from antibiotics, antiseptics, other
25 growth promotants, anaesthetics, and mixtures thereof.

18. A pharmaceutical or veterinary composition for
the treatment of gastrointestinal injuries, diseases or
ulcers, which composition includes

30 an effective amount of a milk product extract
composition including a plurality of cell growth promoting
factors, extracted from milk product in concentrated form;
said factors having basic to approximately neutral
isoelectric points; and

35 a pharmaceutically or veterinarily acceptable
diluent, carrier or excipient therefor.

19. A composition according to claim 18, further
including an effective amount of at least one active
ingredient selected from antibiotics, antiseptics, other
growth promotants, anaesthetics, and mixtures thereof.

-18-

20. A method of treating surface wounds in animals, including humans, which method includes administering to the patient to be treated an effective amount of a pharmaceutical or veterinary composition, which
5 composition includes:

an effective amount of a milk product extract composition including a plurality of cell growth promoting factors, extracted from milk product in concentrated form; said factors having basic to approximately neutral
10 isoelectric points; and

a pharmaceutically or veterinarily-acceptable diluent, carrier or excipient therefor.

21. A method for the treatment of gastrointestinal injuries, diseases or ulcers, which method includes
15 administering to the patient to be treated an effective amount of a pharmaceutical or veterinary composition, which composition includes

an effective amount of a milk product extract composition including a plurality of cell growth promoting
20 factors, extracted from milk product in concentrated form; said factors having basic to approximately neutral isoelectric points; and


a pharmaceutically or veterinarily acceptable diluent, carrier or excipient therefor.

22. A milk product extract composition substantially
25 as hereinbefore described with reference to any one of the examples.

30

35

1/1



INTERNATIONAL SEARCH REPORT

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all)⁶

According to International Patent classification (IPC) or to both National Classification and IPC
Int. Cl.⁷ C07K 3/02, 3/22, 15/06, C12N 5/06, A23C 21/00

II. FIELDS SEARCHED

Minimum Documentation Searched⁷

Classification System

Classification Symbols

IPC

C07K 3/22, 15/06 A23C 21/00

Documentation Searched other than Minimum Documentation
to the extent that such Documents are Included in the Fields Searched⁸

AU:IPC as above

Chemical Abstracts : Keywords "Milk", "Cheese", "Whey"

III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate of the relevant passages ¹²	Relevant to Claim No ¹³
X	US,B,4791193 (Shigeo Okonogi et al) 13 December 1988 (13.12.88) see whole document	1,5
X	AU-B-49227/85 (585543) (Snow Brand Milk Products Co Ltd) 26 June 1986 (26.07.86); see whole document especially page 18 lines 7-16	1
X	AU-B-52480/86 (598186) (Synfina-Oleofina S.A.) 14 August 1986 (14.08.86); see page 1 lines 12-16, page 2 line 32 - page 3 line 2	1
(continued)		

* Special categories of cited documents : ¹⁰

- "A" Document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

"T"

Later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
 "&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search
11 October 1991 (11.10.91)

Date of Mailing of this International Search Report

28 October 91

International Searching Authority

Signature of Authorized Officer

AUSTRALIAN PATENT OFFICE

A W BESTOW



FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

X	AU-B-83720/82 (557353) (Societe Nationale Elf Aquitaine) 18 November 1982 (18.11.82); see page 3 lines 9-26 and page 4 line 13-17	1
X	Kirk-Othmer Encyclopedia of Chemical Technology, 2nd Edition, Vol 13 page 562-69	1
X	AU-B-23326/88 (617126) (CIBA-GEIGY AG.) 1 June 1989 (01.06.89), see whole document	1
A	AU-B-67992/74 (476778) (Boehringer Mannheim GMBH) 23 October 1975 (23.10.75); see whole document	5

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim numbers ..., because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim numbers ..., because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim numbers ..., because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4a

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

- (1) a milk product extract composition and its method of preparation - claims 1-8
 - (2) a cell culture composition and a method for culturing cells - claims 9-15
 - (3) a pharmaceutical or veterinary composition and methods for treating surfaces wounds or gastrointestinal injuries, diseases or ulcers - claims 16-20
1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
 2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
 3. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

1-8
 4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON
INTERNATIONAL APPLICATION NO. T/AU 91/00303

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member			
AU	52480/86	BE	901672	CA	1238633
		DE	3603764	DK	572/86
		ES	8704972	FI	860546
		GB	2171102	IT	1204290
		LU	86252	NL	8600231
		NZ	214924	SE	8600423
		CH	666692	ES	551684
AU	83720/82	FR	2576752	JP	61246198
		NO	860407	US	4667018
		AR	228653	BE	893156
		CH	650905	DE	3218348
		FR	2505615	GB	2098998
		JP	58028233	NL	8201947
		US	4436658	CA	1171723
AU	49227/85	DK	2167/82	IT	1151758
		SE	8203056		
		BE	903886	DE	3544400
		GB	2168982	JP	61145200
US	4791193	FR	2574800	NZ	213985
		US	4668771		
		EP	253395	NZ	221082
AU	67992/74	JP	63152400		
		AR	207222	AT	3167/74
		CH	580390	FR	2226116
		IT	1009848	NL	7405082
AU	23326/88	CA	1023353	GB	1430490
		US	3969337		
		DK	5463/88	EP	313515
AU	23326/88	PT	88626		

END OF ANNEX